Reid Hoffman Steps Down From Microsoft Board to Go All-In on AI Drug Discovery Startup Manus

Reid Hoffman Steps Down From Microsoft Board to Go All-In on AI Drug Discovery Startup Manus

Reid Hoffman, the entrepreneur best known as a co-founder of LinkedIn and as a prolific Silicon Valley investor, has resigned from Microsoft's board of directors after more than a decade in the role. The departure is not a retirement from the tech world — it's the opposite. Hoffman says he is entering what he calls "founder mode" to devote more attention to Manus, his AI drug discovery startup.

Hoffman joined Microsoft's board in 2017, following the company's $26.2 billion acquisition of LinkedIn. In the years that followed, he was present for some of Microsoft's most consequential decisions in the AI era, including the company's landmark investment in OpenAI beginning in 2019. He stepped down from OpenAI's board in 2023 amid broader governance changes, but remained a vocal proponent of responsible AI development.

What Is Manus?

Manus is an AI-powered drug discovery company founded by Hoffman and Dr. Siddhartha Mukherjee, a physician, cancer biologist, and Pulitzer Prize-winning author best known for his book "The Emperor of All Maladies." Mukherjee serves as CEO, while Hoffman takes on the role of co-founder and board chairman.

The startup is applying machine learning to identify and accelerate the development of new therapeutic compounds — a space that has seen explosive interest from venture capital over the past several years. The convergence of biological data, protein structure prediction tools like AlphaFold, and large language models has made AI-assisted drug discovery one of the most technically compelling and commercially promising frontiers in biotechnology.

Hoffman referenced "Move 37" on a recent podcast episode as a metaphor for the kind of unexpected, paradigm-shifting breakthrough he believes Manus is building toward — an allusion to the famous AlphaGo move in the 2016 match against Go champion Lee Sedol that stunned professional players and signaled the arrival of a new level of machine intelligence.

The Strategic Timing

Hoffman's departure from Microsoft's board comes at a significant moment for both the company and the broader tech landscape. Microsoft is navigating intense competition in AI, managing its deep OpenAI partnership, and integrating Copilot features across its enterprise product suite. Losing a board member with Hoffman's unique vantage point — someone who has been involved with LinkedIn, OpenAI, and now an AI biotech startup — is notable even if it is described as a clean transition.

For Manus, having Hoffman in full founder mode rather than split across board commitments could meaningfully accelerate the startup's ability to attract talent, capital, and partnerships in a sector where credibility and connections matter enormously.

Why It Matters

The move underscores a broader trend: top-tier investors and tech veterans are no longer content to watch the AI wave from the boardroom. Hoffman's pivot to an active operating role at a biotech AI startup signals that the most consequential applications of AI over the next decade may not be in software productivity — they may be in medicine, biology, and human health. Manus is one to watch.